U.S. Blood Plasma Collection Market is expected to grow with the CAGR of 6.3% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.
Access Full Report @ https://www.databridgemarketresearch.com/reports/us-blood-plasma-collection-market
U.S. blood plasma collection market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.
The major players dealing in U.S. blood plasma collection market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.
For instance:
- In April 2020, Octapharma AG launched a special project team to explore new therapies for COVID-19. The company also announced that it has also joined other leaders in plasma fractionation in a collaboration to develop a potential plasma-derived hyperimmune immunoglobulin therapy for treating COVID-19.
Cardinal Health is the dominating player in U.S. blood plasma collection market. The other key players existing in the market are STRECK, SIO2 Material Science, Grifols, Instech Laboratories, Inc., CSL Plasma, Greiner Bio-One International GmbH, Cardinal Health, Retractable Technologies, Inc., BD, BPL, Inc., Hemarus Plasma, Liminal Biosciences, Inc., Vitalant, Takeda Pharmaceutical Company Limited, Octapharma AG, and Kedrion S.p.A among Others
Cardinal Health
Cardinal Health headquarters is in USA. The company is focused on the providing Pharmaceutical and medicinal products. The company has several product & service categories including providing Laboratory Products, Lab Equipment, Anatomic Pathology, Blood Bank, Clinical Chemistry, Diagnostic Instruments, General Lab, Haematology Products, Lab Kitting Services, Microbiology Products, Molecular Diagnostics in which Hematology products is the market focused category.
For instance,
- In June 2021, Cardinal Health Nuclear & Precision Health Solutions received the U.S. Food and Drug Administration approval for the new LYMPHOSEEK Paediatric Indication. This will facilitate growth for the company.
The company has wide presence across Americas, Asia-Pacific, Europe, Middle East and Africa. The company also has various subsidiary companies including Abilene Nuclear, LL (Delaware), Allegiance 1, LLC (Delaware), Allegiance (BVI) Holdings Co. Ltd. British Virgin IslandsAllegiance Corporation (Delaware), Allegiance Healthcare (Labuan) Pte. Ltd. (Malaysia), Allegiance Labuan Holdings Pte. Ltd. (Malaysia), Almus Pharmaceuticals Singapore Pte. Ltd.(Singapore) among others.
Octapharm AG
Octapharm AG, founded in the year 1982, headquarter in Lachen, Switzerland. The company is focused in manufacturing medicines which are based on human proteins from human cell lines and human plasma that is sourced from their own plasma donation centers. The company operates its business Critical Care, Haematology, Immunotherapy in which Haematology is the market focused segment..
For instance,
- In June 2021, Octapharma AG has announced that octagam, a human plasma-derived intravenous immunoglobulin (IVIg), has been approved by European and German authorities for adults with dermatomyositis. This helped the company to expand its product portfolio in Germany and Europe.
The company has presence across Asia-Pacific, Europe, Middle East and Africa, South America, North America. The company also has various subsidiaries including Octapharma USA, Inc. (U.S.), Life Therapeutics, Inc. (U.S.), Pyramid Biological Corporation (U.S), Life Gels, Inc. (U.S.) among others.
